NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma
Article
Lee, Eudocia Q, Zhang, Peixin, Wen, Patrick Y et al. (2020). NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma
. CANCER, 126(12), 2821-2828. 10.1002/cncr.32811
Lee, Eudocia Q, Zhang, Peixin, Wen, Patrick Y et al. (2020). NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma
. CANCER, 126(12), 2821-2828. 10.1002/cncr.32811
Lee, Eudocia Q; Zhang, Peixin; Wen, Patrick Y; Gerstner, Elizabeth R; Reardon, David A; Aldape, Kenneth D; deGroot, John F; Pan, Edward; Raizer, Jeffrey J; Kim, Lyndon J; Chmura, Steven J; Robins, H Ian; Connelly, Jennifer M; Battiste, James D; Villano, John L; Wagle, Naveed; Merrell, Ryan T; Wendland, Merideth M; Mehta, Minesh P